Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels01:31

Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels

223
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
223
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

91
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
91
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development of Panel of Three-Dimensional Biomarkers to Identify Gastric Carcinoma and Precancerous Lesions of the Stomach - An Analytical Cross-Sectional Study.

Indian journal of clinical biochemistry : IJCB·2026
Same author

The ultrastructure of a cast: the art and science of renal tubular pathology.

Ultrastructural pathology·2026
Same author

Adrenomedullin overexpression protects mice from experimental bronchopulmonary dysplasia and associated pulmonary hypertension.

American journal of physiology. Lung cellular and molecular physiology·2025
Same author

Exploration of zileuton protective mechanisms against vancomycin-associated nephrotoxicity.

Toxicology and applied pharmacology·2025
Same author

Protection against vancomycin-associated nephrotoxicity by zileuton: role of mitochondria revealed by electron microscopic study.

Ultrastructural pathology·2025
Same author

eGFR Inaccuracy in the Assessment of Living Kidney Transplant Donor Eligibility.

Clinical chemistry·2025

相关实验视频

Updated: Jul 1, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.4K

范科米辛毒性:一项全面的临床病理学研究

Rajesh Nachiappa Ganesh1,2, Angelina Edwards3, Ziad El Zaatari2

  • 1Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.

PloS one
|March 7, 2024
PubMed
概括

范科米的毒性呈现出独特的临床和病理特征,有助于诊断和治疗. 脏活检揭示了独特的特征,区分了万科米辛脏毒性 (VNT) 与急性损伤的其他原因.

更多相关视频

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.4K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.1K

相关实验视频

Last Updated: Jul 1, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.4K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.4K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.1K

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 药理学 药理学是指药理学的学科.
  • 病理学 病理学 病理学

背景情况:

  • 范科米辛对于耐药性感染至关重要,但会导致毒性.
  • 尚不清楚万科米辛脏毒性的临床病理学概况和病原性.
  • 临床研究被并发症和多药学所混;动物模型不足.

研究的目的:

  • 确定万科米辛脏毒性 (VNT) 的临床病理学和形态学概况.
  • 为了区分VNT与急性损伤 (AKI) 的其他原因,在接受活检的患者中.

主要方法:

  • 研究了36名疑似VNT的AKI患者,使用脏活检.
  • 分析了详细的临床,形态和随访数据.
  • 将患者分类为VNT (25) 和非VNT (NO-VNT) (11) 组进行比较.

主要成果:

  • VNT组:具有特征的临床过程 (高温素水平,快速严重的AKI,停止后迅速恢复).
  • VNT组:脏活检结果 (过敏的管间炎,粒状炎症,毒性管状缩,万科米辛体).
  • 显著的临床病理学特征使VNT与NO-VNT区分开来.

结论:

  • 范科米辛的毒性表现出独特的形态和临床特征.
  • 这个概况有助于诊断,治疗指导和预后.
  • 这些发现提供了有关VNT.的病原体的见解.